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ABSTRACT
Retinopathy of prematurity (ROP) is a disease that affects premature infants, where abnormal growth of the
retinal blood vessels can lead to blindness unless treated accordingly. Infants considered at risk of severe ROP are
monitored for symptoms of plus disease, characterized by arterial tortuosity and venous dilation at the posterior
pole, with a standard photographic definition. Disagreement among ROP experts in diagnosing plus disease has
driven the development of computer-based methods that classify images based on hand-crafted features extracted
from the vasculature. However, most of these approaches are semi-automated, which are time-consuming and
subject to variability. In contrast, deep learning is a fully automated approach that has shown great promise in
a wide variety of domains, including medical genetics, informatics and imaging. Convolutional neural networks
(CNNs) are deep networks which learn rich representations of disease features that are highly robust to variations
in acquisition and image quality. In this study, we utilized a U-Net architecture to perform vessel segmentation
and then a GoogLeNet to perform disease classification. The classifier was trained on 3,000 retinal images and
validated on an independent test set of patients with different observed progressions and treatments. We show
that our fully automated algorithm can be used to monitor the progression of plus disease over multiple patient
visits with results that are consistent with the experts’ consensus diagnosis. Future work will aim to further
validate the method on larger cohorts of patients to assess its applicability within the clinic as a treatment
monitoring tool.
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1. INTRODUCTION
Retinopathy of prematurity (ROP) affects premature infants and is a leading cause of childhood blindness within
the United States and globally. The hallmark of the disease is abnormal growth of the retinal vessels which can
lead to scarring and retinal detachment. Although most cases are mild and resolve without intervention, some
infants will develop severe disease and require treatment to mitigate loss of vision. All at risk infants are monitored
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Figure 1. Example retinal photographs from each study cohort (one patient per column, consecutive visits top to bottom).
Significant inter- and intra-subject variations in pathology, pigmentation, illumination, field-of-view and clarity can be
observed.
weekly or biweekly, depending on disease severity, by telemedicine or clinical examination. Treatment is indicated
for type-1 ROP, with aggressive posterior ROP (APROP) being a particularly severe form of the disease that
rapidly progresses to the advanced stages. Treatments include laser photocoagulation therapy and intravitreal
injections of anti-vascular endothelial growth factor agents (anti-VEGF) such as bevacizumab; a humanized
monoclonal antibody.1 Although there are potential advantages to anti-VEGF therapy for treatment-requiring
ROP, the possibility of late disease recurrence warrants more intense monitoring of patients over the course of
several months.2
As intensive neonatal care for premature infants continues to improve, the worldwide prevalence of ROP
is predicted to increase, creating high demand for clinicians with expertise in diagnosing the disease.3 Plus
disease, characterized by increased arterial tortuosity and venous dilation,4 is considered the most important
predictor for progression of ROP.5 Pre-plus is an intermediate level of disease that requires close monitoring for
progression to plus disease.6 High inter-rater disagreement among ROP experts has been well documented for
plus disease diagnosis,7,8 which has motivated research into automated image analysis of retinal photographs.
Most methods apply computationally expensive vessel tracing algorithms to manually segmented vessel images,
or manual identification of vessels and reference points, from which quantitative vessel characteristics are derived
for classification.9,10 In contrast, convolutional neural networks (CNNs) are fully automated and do not require
hand-crafted features. Recent work has shown the robustness of CNNs to a wide range of medical imaging
problems.11,12 CNNs have been applied previously to retinal diseases including diabetic retinopathy,13 macular
degeneration14 and binary classification of plus disease.15 In this study, we present the results of a fully automated
algorithm based on CNNs for automated diagnosis of plus disease across multiple patient visits, demonstrating
its potential as a monitoring tool for ROP.
2. DATA
This study was approved by the Institutional Review Board at the coordinating center (Oregon Health & Science
University [OHSU]) and at each of 7 study centers (Columbia University, University of Illinois at Chicago,
William Beaumont Hospital, Childrens Hospital Los Angeles, Cedars-Sinai Medical Center, University of Miami,
Asociacion para Evitar la Ceguera en Mexico [APEC]), and followed the tenets of the Declaration of Helsinki.
Written informed consent was obtained from parents of all infants enrolled.
Figure 2. Diagram of the pre-processing and classification pipeline to estimate plus disease severity.
A training dataset was created from a database of 4,800 de-identified posterior retinal images captured using
a commercially available camera (RetCam; Natus Medical Incorporated, Pleasanton, CA). These data were
collected as part of the multicenter Imaging and Informatics in ROP (i-ROP) cohort study. A reference standard
diagnosis (RSD) was assigned to each image in the training set using previously published methods,16 which
served as the ground truth for CNN training. For testing, a dataset of 131 images from 46 patients were gathered
and divided into five cohorts based on the RSDs observed over multiple visits; no progression, progression to
pre-plus, progression to plus, progression to APROP, and bevacizumab-treated. No images from patients in the
testing set were included in the training set. Representative example images from each cohort are shown in
Figure 1.
3. METHODS
3.1 Pre-processing
Figure 2 shows a diagram of the analysis pipeline. For preprocessing, all images were resized to 640 x 480 pixels.
A patch-based (48 x 48 pixel) U-Net17 CNN architecture was then trained on 200 manually segmented retinal
images, minimizing a cross-entropy loss function with stochastic gradient descent and a learning rate of 0.01.
The trained U-Net was then used to segment the entire training set by extracting all overlapping patches with
an 8 pixel stride. Overlapping regions were averaged to produce an image in the range 0.0 - 1.0. An approximate
binary mask was computed by applying a simple threshold to the original image. This approximation was then
used to calculate the centroid and radius of a circle enclosing the retinal field of view. This refined mask was
applied to the segmentation image to remove incorrectly segmented regions around the periphery. The training
images were then cropped and resized to 224 x 224 pixels with bicubic interpolation. To balance the training set,
the images were augmented by means of 90 degree rotations and horizontal/vertical flips, increasing the total
number of images eight-fold. A subset of 3,024 images (1,008 from each class) was randomly sampled from the
augmented set and used for CNN training.
3.2 Severity score
The Inception-v1 (GoogLeNet)18 CNN architecture was used for image classification. The weights were initialized
following training on the ImageNet19 database (∼1.2 million images); a strategy commonly referred to as transfer
learning.20 The final softmax activation was modified to produce three outputs; normal, pre-plus or plus. The
network was then trained for 100 epochs with a constant learning rate of 0.0001 using stochastic gradient descent,
with cross-entropy loss. These hyperparameters were tuned by cross-validation within the training set. Inference
was performed on the testing images following pre-processing, yielding probabilities for each of the three disease
classes. A severity score was then computed as a weighted sum of the probabilities
S = P (Normal) + 2P (PreP lus) + 3P (Plus) (1)
ranging from 1.0 (normal) to 3.0 (plus). This severity score was used to assess the same eye patients over multiple
visits. The elapsed time between patient visits was not identical.
3.3 Feature visualization
To visualize changes in appearance due to pathology over multiple patient visits, t-distributed stochastic neighbor
embedding (t-SNE) was used to map the high-dimensional CNN features into a two-dimensional latent space.21
The fully-connected network at the end of the GoogLeNet architecture was removed, and the output of the
global average pooling layer used to extract a vector of image features x ∈ R1024 for each image in the test set.
t-SNE was then applied to the features of the test set X = {x1,x2, ...,xn} ,xi ∈ R1024 to produce an embedding
Y = {y1,y2, ...,yn} ,yi ∈ R2, which was visualized as a scatter plot.
4. RESULTS AND DISCUSSION
4.1 Severity scores over time
Figure 3 shows the results of automated diagnosis over multiple visits for the five patient cohorts. Plots show
the mean and standard deviation severity score at each visit. Infants reported as having no ROP progression (n
= 6, 3 or 4 visits) show no noticeable signs of disease across all visits, with negligible variance across patients.
The Pre-Plus cohort shows a steady increase to intermediate severity, whereas the Plus (n = 8, 3 or 4 visits)
and APROP (n = 6, 2 or 3 visits) patients both exhibit a more pronounced increase to maximal severity. The
rate of progression in APROP appears to be both rapid and more varied between patients across all visits.
Bevacizumab-treated infants (n = 15, 2 or 3 visits) show regression after treatment (between visits 0 and 1)
followed by varying degrees of progression at visit 2. This is consistent with trends observed clinically following
bevacizumab treatment.2,22
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Figure 3. Mean disease severity plotted for five patient cohorts over multiple visits. The severity score is calculated based
on the output probabilities of the CNN (ranging from 1.0 3.0). Error bars correspond to one standard deviation.
4.2 Disease trajectories in feature space
The t-SNE disease trajectories are shown in Figure 4, colorized by patient cohort. The bevacizumab-treated
cohort is omitted for clarity. The size of individual points in the space is proportional to the severity score for
that image. Images from the same patient are connected by vectors that denote disease trajectories over time.
It is apparent that the t-SNE latent space separates disease stages, with non-pathological images clustered in
the upper left and severe pathology on the lower right.
Figure 4. Disease trajectory plots in t-SNE latent space (arbitrary units). Each point corresponds to in an individual
image, with individual patients indicated by a set of connected vectors. Vector thickness is proportional to disease severity.
The bevacizumab-treated cohort is omitted for clarity.
5. CONCLUSIONS
In this study, we present a deep learning-based algorithm for monitoring plus disease in ROP. Application of
the method to a small dataset of patients with different disease characteristics yields promising results, showing
trends consistent with the reference standard diagnoses. t-SNE visualization of learned image features allows
for direct comparison of images and patients in a common space. To our knowledge, this is the first application
of a fully automated method for monitoring ROP over time. Future work will focus on application of the
method to larger cohorts of patients, and interpretation of the features learned by the algorithm. The proposed
method shows potential for earlier identification of patients that are likely to progress to ROP and assist clinical
decision-making.
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